Literature DB >> 22445743

Nephrotoxicity profiles and threshold dose values for [177Lu]-DOTATATE in nude mice.

Johanna Svensson1, Johan Mölne, Eva Forssell-Aronsson, Mark Konijnenberg, Peter Bernhardt.   

Abstract

INTRODUCTION: In peptide receptor radionuclide therapy for neuroendocrine tumors the main dose-limiting tissue is found in the kidneys because of tubular reabsorption and retention of radioactivity. The aim of this study was to quantify late effects in renal cortex of nude mice exposed to high amounts of [(177)Lu]-DOTA-Tyr(3)-octreotate ([(177)Lu]-DOTATATE), and to determine whether a threshold dose value exists for these findings.
METHODS: Nude mice were exposed to 90, 120 or 150 MBq of [(177)Lu]-DOTATATE. Renal toxicity was evaluated up to 6 months after injection. Blood samples were collected to examine renal functional markers, and after sacrifice at 6 months changes in renal morphology were explored. Tissue damage was estimated by quantifying the relative area of the different subunits in the renal cortex using point counting. Additional morphological signs of radiation damage were also noted. The absorbed doses to the kidneys were estimated by previously determined kidney pharmacokinetics and Monte Carlo simulations for different assumptions regarding the activity distribution.
RESULTS: Increased serum creatinine and urea values indicated long-term renal toxicity. The tissue area occupied by proximal tubules decreased with increasing doses of [(177)Lu]-DOTATATE, whereas the other subunits in cortex slightly increased. The mean absorbed dose in the renal cortex for [(177)Lu]-DOTATATE was estimated to be 35-58 Gy for the different groups of animals. A dose-response relationship was observed for proximal tubular damage, and a threshold dose value of 24 Gy (BED 37 Gy) was determined.
CONCLUSIONS: Selective morphological changes in kidney cortex of nude mice were quantified and appeared in a dose dependent manner after injection of high amounts of [(177)Lu]-DOTATATE.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22445743     DOI: 10.1016/j.nucmedbio.2012.02.003

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  16 in total

1.  Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer.

Authors:  Wolfgang P Fendler; Andreea D Stuparu; Susan Evans-Axelsson; Katharina Lückerath; Liu Wei; Woosuk Kim; Soumya Poddar; Jonathan Said; Caius G Radu; Matthias Eiber; Johannes Czernin; Roger Slavik; Ken Herrmann
Journal:  J Nucl Med       Date:  2017-05-25       Impact factor: 10.057

2.  Potential Biomarkers for Radiation-Induced Renal Toxicity following 177Lu-Octreotate Administration in Mice.

Authors:  Emil Schüler; Maria Larsson; Toshima Z Parris; Martin E Johansson; Khalil Helou; Eva Forssell-Aronsson
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

3.  Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with (177)Lu-octreotate.

Authors:  Johanna Dalmo; Emelie Westberg; Lars Barregard; Lisa Svedbom; Martin Johansson; Margareta Törnqvist; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2014-10-31       Impact factor: 3.138

4.  Distinct microRNA expression profiles in mouse renal cortical tissue after 177Lu-octreotate administration.

Authors:  Emil Schüler; Toshima Z Parris; Khalil Helou; Eva Forssell-Aronsson
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

5.  Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.

Authors:  Kristell L S Chatalic; Sandra Heskamp; Mark Konijnenberg; Janneke D M Molkenboer-Kuenen; Gerben M Franssen; Marian C Clahsen-van Groningen; Margret Schottelius; Hans-Jürgen Wester; Wytske M van Weerden; Otto C Boerman; Marion de Jong
Journal:  Theranostics       Date:  2016-04-12       Impact factor: 11.556

6.  Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate.

Authors:  Stephanie Haller; Giovanni Pellegrini; Christiaan Vermeulen; Nicholas P van der Meulen; Ulli Köster; Peter Bernhardt; Roger Schibli; Cristina Müller
Journal:  EJNMMI Res       Date:  2016-02-09       Impact factor: 3.138

Review 7.  Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy.

Authors:  Jun Zhao; Min Zhou; Chun Li
Journal:  Cancer Nanotechnol       Date:  2016-11-16

8.  A Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in Mice.

Authors:  Giovanni Pellegrini; Klaudia Siwowska; Stephanie Haller; Daniel J Antoine; Roger Schibli; Anja Kipar; Cristina Müller
Journal:  Pharmaceuticals (Basel)       Date:  2017-06-21

9.  177Lu Labeled Cyclic Minigastrin Analogues with Therapeutic Activity in CCK2R Expressing Tumors: Preclinical Evaluation of a Kit Formulation.

Authors:  Christine Rangger; Maximilian Klingler; Lajos Balogh; Zita Pöstényi; Andras Polyak; Dariusz Pawlak; Renata Mikołajczak; Elisabeth von Guggenberg
Journal:  Mol Pharm       Date:  2017-08-07       Impact factor: 4.939

10.  Cadmium Nephrotoxicity Is Associated with Altered MicroRNA Expression in the Rat Renal Cortex.

Authors:  Michael J Fay; Lauren A C Alt; Dominika Ryba; Ribhi Salamah; Ryan Peach; Alexander Papaeliou; Sabina Zawadzka; Andrew Weiss; Nil Patel; Asad Rahman; Zyaria Stubbs-Russell; Peter C Lamar; Joshua R Edwards; Walter C Prozialeck
Journal:  Toxics       Date:  2018-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.